Thalassemia testing. Simplifed.
Comprehensive NGS testing for thalassemia and sickle cell disease. Now with β-modifier detection, robust CNV analysis, and a streamlined workflow.
Devyser Thalassemia v2 is a first-of-its-kind CE-marked (IVDR) NGS solution for comprehensive genetic testing in sickle cell disease and alpha- and beta-thalassemia. It identifies SNVs, indels, CNVs, challenging α-globin deletions, and clinically relevant β-globin modifiers, enabling fast, robust, and clinically meaningful results for diagnostic laboratories.
- Broad coverage and comprehensive detection
- Efficient NGS workflow, built for reliable results
- Dedicated analysis pipeline
Dedicated analysis pipeline, straightforward to use
Performance at a glance*
>97.6%
PPA
>99.9%
NPA
>99.9%
OPA
Positive percent agreement
Negative percent agreement
Overall percent agreement
*Clinical performance evaluated on 433 samples (426 residual clinical gDNA from individuals tested for suspected thalassemia or sickle cell disease + 7 cell-line gDNA samples) at two external ISO 15189-accredited European laboratories.
